Adjuvant pazopanib does not PROTECT against recurrence of high risk initially localised renal cell cancer, but does provide novel insights
Journal of Clinical Oncology
American Society of Clinical Oncology
MetadataShow full item record
Stewart, G., Leibovick, B., Negrier, S., & Figlin, R. (2017). Adjuvant pazopanib does not PROTECT against recurrence of high risk initially localised renal cell cancer, but does provide novel insights. Journal of Clinical Oncology, 35 (35), 3895-3897. https://doi.org/10.1200/JCO.2017.75.4242
Improved post-surgical management of the 70% of all renal cell cancer (RCC) patients who present to urological surgeons with initially localised RCC, to prevent subsequent progression, is an area of great need within uro-oncology.
GD Stewart has received educational grants from Pfizer and Intuitive Surgical; consultancy fees from Pfizer, EUSA Pharma and Cambridge Medical Robotics; Travel expenses from Pfizer and Speaker fees from Pfizer. RA Figlin has received research funding from Peloton, BMS, Argos Therapeutics, Exilexis, and Cerulean; consulting fees from Novartis, Pfizer, Nektar, Peloton, Calithera, and Acceleron. S Negrier reports honoraria from Pfizer, Novartis, EUSA Pharma, Ipsen Biotech and Bristol-Myers Squibb. BC Leibovich declares no conflicts of interest.
Embargo Lift Date
External DOI: https://doi.org/10.1200/JCO.2017.75.4242
This record's URL: https://www.repository.cam.ac.uk/handle/1810/271606